61.18
0.84 (1.39%)
| Penutupan Terdahulu | 60.34 |
| Buka | 59.17 |
| Jumlah Dagangan | 759,602 |
| Purata Dagangan (3B) | 739,668 |
| Modal Pasaran | 2,334,632,704 |
| Harga / Buku (P/B) | 4.38 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| EPS Cair (TTM) | -3.89 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.64% |
| Nisbah Semasa (MRQ) | 37.65 |
| Aliran Tunai Operasi (OCF TTM) | -101.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -66.74 M |
| Pulangan Atas Aset (ROA TTM) | -16.25% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.33% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Disc Medicine, Inc. | Menurun | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.60 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 10.65% |
| % Dimiliki oleh Institusi | 99.13% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 125.00 (Cantor Fitzgerald, 104.32%) | Beli |
| Median | 94.00 (53.65%) | |
| Rendah | 79.00 (Wells Fargo, 29.13%) | Beli |
| Purata | 97.50 (59.37%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 65.91 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 02 Mar 2026 | 79.00 (29.13%) | Beli | 66.54 |
| 17 Feb 2026 | 78.00 (27.49%) | Beli | 65.57 | |
| Truist Securities | 27 Feb 2026 | 83.00 (35.67%) | Beli | 66.62 |
| BMO Capital | 17 Feb 2026 | 100.00 (63.45%) | Beli | 65.57 |
| Cantor Fitzgerald | 17 Feb 2026 | 125.00 (104.32%) | Beli | 65.57 |
| Stifel | 17 Feb 2026 | 110.00 (79.80%) | Beli | 65.57 |
| Wedbush | 17 Feb 2026 | 88.00 (43.84%) | Beli | 65.57 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FRANCHI JEAN M. | - | 66.89 | -353 | -23,612 |
| SAVAGE WILLIAM JACOB | - | 66.54 | -7,378 | -490,932 |
| Jumlah Keseluruhan Kuantiti Bersih | -7,731 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -514,544 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 66.72 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SAVAGE WILLIAM JACOB | Pegawai | 02 Mar 2026 | Jual automatik (-) | 7,378 | 66.54 | 490,932 |
| FRANCHI JEAN M. | Pegawai | 25 Feb 2026 | Jual automatik (-) | 353 | 66.89 | 23,612 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2026 | Pengumuman | Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 |
| 12 Jan 2026 | Pengumuman | Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer |
| 07 Jan 2026 | Pengumuman | Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |